SEC FORM 3

Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Heft Robert

(Last)

(First)

(Middle)

C/O ELOXX PHARMACEUTICALS, INC.

950 WINTER STREET, 4TH FLOOR NORTH

(Street)

WALTHAM

02451

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/19/2017

3. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ SVOND ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	12/14/2024	Common Stock	291,499⁽³⁾	$0.96⁽³⁾	D
Stock Option (Right to Buy)	⁽²⁾	12/14/2026	Common Stock	48,916⁽³⁾	$1⁽³⁾	D

Explanation of Responses:

1. The option vested over a three-year period commencing on January 24, 2014 in twelve equal quarterly installments and became fully vested and exercisable as of January 24, 2017.

2. The option vests over a three-year period commencing on January 24, 2016 in twelve equal quarterly installments.

3. Exercise price and number of option shares, as applicable, have been adjusted to reflect the Issuer's 1-for-20 reverse stock split of its issued and outstanding shares of common stock effected on December 19, 2017.

Remarks:

Exhibit 24 - Power of Attorney. Gregory Weaver, Chief Financial Officer, is signing on behalf of Dr. Robert Heft pursuant to a Power of Attorney dated December 16, 2017, which is attached hereto as an exhibit.

	/s/ Gregory Weaver, Attorney in Fact	12/29/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.